Successful treatment of metastatic malignant melanoma with Viscum album extract (Iscador® M)

Journal of Alternative and Complementary Medicine

Volumn 13, Issue 4, 2007, Pages 443-445

  Kirsch, Angelika ^a  

^a Praxis Internal Medicine FMH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ISCADOR M; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT;

ADJUVANT THERAPY; AGED; ARTICLE; AXILLARY LYMPH NODE; CANCER INFILTRATION; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CASE REPORT; DERMIS; DRUG EFFICACY; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MELANOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME; ULTRASOUND;

ADJUVANTS, PHARMACEUTIC; AGED; ANTINEOPLASTIC AGENTS; HUMANS; LIVER NEOPLASMS; MALE; MELANOMA; PLANT EXTRACTS; PLANT PROTEINS; SKIN NEOPLASMS; TREATMENT OUTCOME; VISCUM ALBUM;

EID: 34249002679     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2007.6175     Document Type: Article

References (16)

1. Garbe C. Epidemiology of skin cancer. In: Garbe C, Dummer R, Kaufmann R, Tilgen W, eds. Dermatologic Oncology [in German]. Berlin, Heidelberg, New York, Tokyo; Springer, 1997:40-56.
2. Rager EL, Bridgeford EP, Ollila DW. Cutaneous melanoma: Update on prevention, screening, diagnosis, and treatment. Am Fam Physician 2005;72:269-276. [review]
3. Schmidt M, Hölzel D. Clinical-Epidemiologic Data on the Malignant Melanoma from the Area of the Tumor Centre of Munich, 5th ed. [in German]. Munich: Tumorzentrum München und W. Zuckschwerdt Verlag GmbH, 2006.
4. Khan MA, Andrews S, Ismail-Khan R, et al. Overall and progression-free survival in metastatic melanoma: Analysis of a single-institution database. Cancer Control 2006;13:211-217.
5. Scoggins CR, Ross MI, Reintgen DS, et al. and the Sunbelt Melanoma Trial. Gender-related differences in outcome for melanoma patients. Ann Surg 2006;243:693-698; discussion 698-700.
6. Weber K, Mengs U, Schwarz T, et al. Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs. Arzneim Forsch Drug Res 1998;48: 497-502.
7. Augustin M, Bock PR, Hanisch J, et al. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract: Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arzneim Forsch Drug Res 2005;55:38-49.
8. Hajto T, Hostankak, Fornalski M, Kirsch A. Antitumoral activity of the immunomodulatory active beta-galactosid-specific mistellectins by the clinical application of mistletoe extracts (Iscador®) [in German]. Dtsch Ztschr Onkol 1991:23.
9. Kleeberg UR, Suciu S, Brocker EB, et al.; EORTC Melanoma Group in cooperation with the German Cancer Society (DKG). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004;40:390-402.
10. Gerhard I. Problems of randomized studies in complementary medicine demonstrated in a study on mistletoe treatment of patients with breast cancer. Forsch Komplementarmed Klass Naturheilkd 2004;11:150-157.
11. Molassiotis A. Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer 2006;14:260-267.
12. Kienle GS. Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 2003;8:109-119.
13. Ernst E. Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 2003;107:262-267.
14. Kiene H. Pluralism in medicine - pluralism or therapeutic evaluation? Z Arztl Fortbild Qualitatssich 2005;99:261-262.
15. Kienle GS. Improving the quality of therapeutic reports of single cases and case series in oncology - criteria and checklist. Altern Ther Health Med 2004;10:68-72.
16. Kiene H. What is cognition-based medicine? Z Arztl Fortbild Qualitatssich 2005;99:301-306.